Loss of expression of the growth inhibitory gene GADD45γ, in human pituitary adenomas, is associated with CpG island methylation

Oncogene

Volumn 23, Issue 4, 2004, Pages 936-944

  Bahar, Adil ^a   Bicknell, John E ^a   Simpson, David J ^a   Clayton, Richard N ^a   Farrell, William E ^a  

^a KEELE UNIVERSITY   (United Kingdom)

Author keywords

CpG island methylation; GADD45 ; Pituitary adenomas

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 45;

ARTICLE; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; EPIGENETICS; GADD45 GAMMA GENE; GENE MUTATION; GENE SILENCING; GENETIC CODE; GENETIC TRANSCRIPTION; HETEROZYGOSITY LOSS; HUMAN; HUMAN TISSUE; HYPOPHYSIS ADENOMA; HYPOPHYSIS TUMOR; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SEQUENCE ANALYSIS;

ADENOMA; BASE SEQUENCE; CPG ISLANDS; DNA METHYLATION; DNA PRIMERS; DNA, NEOPLASM; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LOSS OF HETEROZYGOSITY; MOLECULAR SEQUENCE DATA; PITUITARY NEOPLASMS; POLYMERASE CHAIN REACTION; PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 1342322685     PISSN: 09509232     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.onc.1207193     Document Type: Article

References (38)

1. Asa SL and Ezzat S. (1998). Endocr. Rev., 19, 798-827.
2. Azam N, Vairapandi M, Zhang W, Hoffman B and Liebermann. (2001). J. Biol. Chem., 276, 2766-2774.
3. Bates AS, Farrell WE, Bicknell EJ, Talbot AJ, Broome JC, Perrett CW, Thakker RV and Clayton RN. (1997). J. Clin. Endocrinol. Metab., 82, 818-824.
4. Baylin SB, Herman JG, Graff JR, Vertino PM and Issa J-P. (1998). Advances in Cancer Research, Vande Woude GF and Kleine G (eds). Academic Press: San Diego, CA, pp. 141-196.
5. Boggild MD, Jenkinson S and Pistorello M et al. (1994). J. Clin. Endocrinol Metab., 78, 387-392.
6. Chomczynski P and Sacchi N. (1987). Anal. Biochem., 162, 156-159.
7. Clark SJ and Melik J. (2002). Oncogene, 21, 5380-5387.
8. Davis JRE, Farrell WE and Clayton RN. (2001). Reproduction, 121, 363-371.
9. Esteller M, Corn PG, Baylin SB and Herman JG. (2001). Cancer Res., 61, 3225-3229.
10. Farrell WE and Clayton RN. (2000). Front Neuroendocrinol, 21, 174-198.
11. Fearon ER and Vogelstein B. (1990). Cell, 61, 759-767.
12. Fornace Jr AJ, Alamo Jn I and Hollander MC. (1998). Proc. Natl. Acad. Sci. USA, 85, 8800-8804.
13. Frost SJ, Simpson DJ, Clayton RN and Farrell WE. (1999). Mol. Endocrinol., 13, 1801-1810.
14. Grigg GW. (1996). DNA Seq., 6, 189-198.
15. Herman JG, Graff JR, Myöhänen S, Nelkin BD and Baylin SB. (1996). Proc. Natl. Acad Sci. USA, 93, 9821-9826.
16. Hibberts NA, Simpson DJ, Bicknell JE, Broome JC, Hoban PR, Clayton RN and Farrell WE. (1999). Clin. Can. Res., 5, 2133-2139.
17. Huang TH-M, Perry MR and Laux DE. (1999). Hum. Mol. Genet., 8, 459-470.
18. Jaffrain-Rea ML, Ferretti E, Toniato E, Cannita K, Santoro A, Di Stefano D, Ricevuto E, Maroder M, Tamburrano G, Cantore G, Gulino A and Martinotti S. (1999). Clin. Endocrinol., 51, 317-325.
19. Knudson AG. (1996). J. Cancer Res. Clin. Oncol., 122, 135-140.
20. Korabiowska M, Betke H, Brinck U, Grohmann U, Honig JF and Droese M. (1999). In vivo, 13, 483-485.
21. Pei L and Melmed S. (1997). Mol. Endocrinol., 11, 433-441.
22. Ruebel KH, Jin L, Zhang S, Scheithauer BW and Lloyd RV. (2001). Endocr. Pathol., 12, 281-289.
23. Seemann N, Kuhn D, Wrocklage C, Keyvani K, Hackl W, Buchfelder M, Fahlbusch R and Paulus W. (2001). J. Pathol., 193, 491-497.
24. Simpson DJ, Bicknell EJ, McNicol AM, Clayton RN and Farrell WE. (1999a). Genes Chromosomes Cancer, 24, 328-336.
25. Simpson DJ, Clayton RN and Farrell WE. (2002). Oncogene, 21, 1217-1224.
26. Simpson DJ, Frost SJ, Bicknell JE, Broome JC, McNicol AM, Clayton RN and Farrell WE. (2001). Carcinogenesis, 22, 1149-1154.
27. Simpson DJ, Hibberts NA, McNicol AM, Clayton RN and Farrell WE. (2000). Cancer Res., 60, 1211-1216.
28. Simpson DJ, Magnay J, Bicknell JE, Barkan AL, McNicol AM, Clayton RN and Farrell WE. (1999b). Cancer Res., 59, 2703-2709.
29. Takekawa M and Saito H. (1998). Cell, 95, 521-530.
30. Tereda T, Kovaks K, Stefaneanu L and Hovarths E. (1995). Endocr. Pathol., 6, 301-310.
31. Turker MS. (2002). Oncogene, 21, 5388-5393.
32. Wan Y, Wang Z, Shao Y, Xu Y, Voorhees J and Fisher G. (2000). Int. J. Med., 6, 683-688.
33. Woloschak M, Yu A and Post KD. (1997). Mol. Carcinogenesis, 19, 221-224.
34. Yan PS, Perry MR, Laux DE, Asare AL, Caldwell CW and Huang TH-M. (2000). Clin. Cancer Res., 6, 1432-1438.
35. Zhang W, Bae I, Krishnaraiu K, Azam M, Fan W, Smith K, Hoffman B and Liebermann DA. (1999a). Oncogene, 18, 4899-4907.
36. Zhang W, Hoffman B and Liebermann DA. (2001). Int. J. Oncol., 18, 749-757.
37. Zhang X, Horwitz GA, Heaney AP, Nakashima M, Bronstein M and Melmed S. (1999b). J. Clin. Endocrinol. Metab., 84, 761-767.
38. Zhang X, Sun H, Danila DC, Johnson SR, Zhou Y, Swearingen B and Klibanski A. (2002). J. Clin. Endocrinol. Metab., 87, 1262-1267.